Company: IMRX
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001790340-25-000104
Chunk: 351

Company: Immuneering Corp
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 1
Chunk 351
---
,454 $10,652 $(198)(1.9)%

Research and development expenses decreased by approximately $0.2 million, or 1.9%, to approximately $10.5 million for the three months ended June 30, 2025 as compared to approximately $10.7 million for the three months ended June 30, 2024. The decrease of approximately $0.2 million was primarily due to a decrease in indirect research and development expenses of approximately $0.4 million, which was primarily driven by decreased employee-related costs (including due to a lower employee headcount) of $0.3 million, stock-based compensation costs of $0.1 million, in addition to facilities and other expenses of $15 thousand. The remaining variance was driven by an increase of approximately $0.2 million related to direct research and development expenses, including a $1.4 million increase in expenses related to atebimetinib (IMM-1-104) offset by a $0.9 million decrease in expenses related to IMM-6-415, and decreased preclinical spend of approximately $0.3 million due to the Company's prioritization of atebimetinib. 

28

General and Administrative

The following table summarizes the components of our general and administrative expenses for the periods indicated:

Three Months Ended June 30,Change20252024$% (in thousands, except percentages)Employee-related costs$2,114 $2,054 $60 2.9 %Stock-based compensation expense915 983 (68)(6.9)%Professional fees942 726 216 29.8 %Facilities and other allocated expenses67 61 6 9.8 %Other258 430 (172)(40.0)%Total general and administrative$4,296 $4,254 $42 1.0 %

General and administrative expenses increased by approximately $42 thousand, or 1.0%, to approximately $4.3 million for the three months ended June 30, 2025 compared to approximately $4.3 million for the three months ended June 30, 2024. The increase of approximately $42 thousand was primarily due to $0.2 million increase in professional fees for accounting, auditing and legal services and $0.1 million increase in employee-related costs, offset by decreased stock-based compensation expense of approximately $0.1 million and $0.2 million of other costs.

Am